Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Niraparib + TSR-042 for Endometrial Cancer
Recruiting1 awardPhase 2
Calgary, Alberta
This trial is testing an investigational drug to see if it can help treat endometrial cancer that has come back or is advanced. The drug works by targeting a protein called PARP, and researchers want to see if it is more effective in patients whose cancer has a specific genetic change.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service